The rise pharmaceutical industry in China

The rise pharmaceutical industry in China 

Five different vaccines are currently being tested on patients in China. The Sinovac Biotech laboratory recently announced a partnership with the Butantan Institute in São Paulo to conduct its phase III trial in Brazil. It already has its white and orange box and it even has a name: "Coronavac". The vaccine developed by Sinovac Biotech is still far from its approval, but the Chinese laboratory has already started production.

Based in Beijing, Sinovac is one of the few Chinese laboratories authorized to conduct clinical trials. Five different vaccines are currently being tested on patients in China. With millions of dollars in financial support, China has embarked on a race against the clock to quickly release a vaccine against Covid-19 which would not only make it possible to immunize its population as quickly as possible on time. where Beijing is facing a resurgence of the epidemic but also to obtain international recognition. A future Chinese vaccine would be "a global public good," promised Chinese President Xi Jinping.

China have big pharma firms

• Sinopharm Group
• Shanghai Pharmaceutical
• Guangdong Jiuzhoutong Pharmaceutical
• China Resources Pharmaceutical Group
• Jointown Pharmaceutical Group
• Nanjing Pharmaceutical
• Guangzhou Pharmaceuticals
• Chongqing Pharmaceutical
• Huadong Medicine
• Sichuan Kelun Pharmaceutical

source https://seoagencychina.com/list-of-pharmaceutical-distributors-in-china/

Other country may localise pharmaceutical production in their own land

This is a good thing because it is a question of sovereignty to secure access to medicines for patients. These incentives will first benefit the pharmaceutical groups. Then they must be well reflected at the level of subcontractors. In concrete terms, the relocation of the manufacture of paracetamol is not only symbolic because the country was in tension at the start of the crisis on this drug. It is very good that UPSA and Sanofi are working on this subject with my colleague and competitor Seqens. However, the deep issue is not the relocation of paracetamol. The problem arises more on drugs said to be of major therapeutic interest in the fields of oncology or, for example, diseases affecting the central nervous system. This type of medicine must be able to be produced in part in Europe.

Top European Pharma Firms 

There are a few large laboratories, such as Sanofi, Servier and Pierre Fabre, and above all a fragmented set of SMEs and mid-cap companies, most of which work on contract. Faced with Asian competition, players have emerged over the past fifteen years. This is the case of Seqens, Novasep, Axyntis and Minafin who today represent the leaders of the sector in France. All have consolidated sets of assets to recover momentum.


However, in the past 20 years, the value chain has been drastically changed. Europe, which produced almost 80% of this fine chemicals, has passed the baton to Asia, China and India at the head.